ReviewWorld journal of hepatology2015
Liver transplantation for cholangiocarcinoma: Current status and new insights.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.Liver cancer · 2026Review
- The coefficient of variation of CT values for predicting lymph node metastasis in extrahepatic cholangiocarcinoma.PloS one · 2026Article
- Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.Journal of liver transplantation · 2025Article
- Evolution of transplant oncology indications: a single-institution experience over 40 years.Updates in surgery · 2024Article
- Indications and outcomes of liver transplantation for liver tumors in the United States.Surgery in practice and science · 2024Article
- Article
- The State of Systematic Therapies in Clinic for Hepatobiliary Cancers.Journal of hepatocellular carcinoma · 2024Review
- Liver transplantation in metastatic colorectal cancer: are we ready for it?British journal of cancer · 2023Review
- Prognostic influence for hilar cholangiocarcinoma and comparisons of prognostic values of Mayo staging and TNM staging systems.Medicine · 2022Article
- Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant.World journal of clinical oncology · 2022Article
- Cholangiocarcinoma: a review of the literature and future directions in therapy.Hepatobiliary surgery and nutrition · 2022Review
- The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation.Cancers · 2022Article
- Focal liver lesions in cirrhosis: Role of contrast-enhanced ultrasonography.World journal of radiology · 2022Review
- Review
- Liver transplantation for malignant liver tumors.iLIVER · 2022Review
- Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.World journal of gastrointestinal oncology · 2021Review
- New Indications for Liver Transplantation.Journal of clinical medicine · 2021Review
- Review
- Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.Journal of gastrointestinal cancer · 2021Article
- Interventional Treatment for Cholangiocarcinoma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma is a malignant tumor of the biliary system that can be classified into intrahepatic (iCCA), perihiliar (phCCA) and distal. Initial experiences with orthotopic liver transplantation (OLT) for patients with iCCA and phCCA had very poor results and this treatment strategy was abandoned. In the last decade, thanks to a strict selection process and a neoadjuvant chemoradiation protocol, the results of OLT for patients with non-resectable phCCA have been shown to be excellent and this strategy has been extended worldwide in selected transplant centers. Intrahepatic cholangiocarcinoma is a growing disease in most countries and can be diagnosed both in cirrhotic and in non-cirrhotic livers. Even though OLT is contraindicated in most centers, recent investigations analyzing patients that were transplanted with a misdiagnosis of HCC and were found to have an iCCA have shown encouraging results. There is some information suggesting that patients with early stages of the disease could benefit from OLT. In this review we analyze the current state-of-the-art of OLT for cholangiocarcinoma as well as the new insights and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.